The Biological Computing

About The Biological Computing

The Biological Computing Company (TBC), formerly Biological Black Box (BBB), is developing a new class of computing that integrates living neurons with silicon-based artificial intelligence systems. The company was founded in 2021 by neurosurgeon-scientists Alex Ksendzovsky (CEO) and Jon Pomeraniec (COO). The two have partnered for decades through medical school and research positions, and their work on the brain's computing capabilities led them to establish the company.

TBC's core technology involves using living neural networks to enhance the performance, efficiency, and scalability of modern AI models, particularly for workloads like computer vision and generative video. Instead of building "brain-inspired" silicon, the company harnesses the intrinsic computational power of neurons. Their process involves encoding real-world data, such as images, into living neurons and then decoding the neural activity into richer data representations. These representations are then mapped onto state-of-the-art AI models via the company's modular "Biological Adapters." This approach aims to complement existing AI architectures rather than replacing them entirely.

The firm operates on a business model that includes subscription-based access to its technologies for clients such as AI researchers, developers, and businesses. By integrating TBC's platforms, clients can potentially achieve significant benchmark gains, reduce training costs, and improve the stability of their AI systems. In parallel to its hardware, TBC is developing an "Algorithm Discovery" platform that uses these biological insights to inform the design of novel AI systems beyond current transformer-based architectures. The company asserts this can lead to models that require less power, generate higher accuracy, and learn continuously with minimal training.

In February 2026, TBC announced a $25 million seed funding round led by Primary Ventures, coinciding with the opening of its flagship lab in San Francisco. This funding supports customer deployments and the continued development of its bio-computing platform.